Table 1.
Post-transplant follow-up of recipient monkeys
| Monkey | Pig donor genetics |
Post-Tx Follow-up (days) |
Presence of intravascular catheters post-Tx (days) |
2nd dose of ATG |
Anti- CD154mAb type |
Anti-CD154mAb maintenance dose (mg/kg/week) |
Anti-CD154mab serum trough levels (μg/mL) mean±SD |
|---|---|---|---|---|---|---|---|
| 1 | GTKO | 8 | 8 | y | ABI793 | 5-15 | 641 |
| 2 | WT | 270 | 21 | y | ABI793 | 5-15 | 1138±440 |
| 3 | GTKO | 70 | 42 | y | ABI793 | 5-15 | 1021±489 |
| 4 | WT | 41 | 41 | y | ABI793 | 5-15 | 1388±578 |
| 5 | hCD46 | 98 | 98 | y | ABI793 | 5-15 | 1075±514 |
| 6 | hCD46 | 131 | 75 | y/n* | ABI793 | 5-15 | 609±165 |
| 7 | hCD46 | 120 | 0 | n | ABI793 | 5-15 | 944±46 |
| 8 | hCD46 | 183 | 40 | n/y* | ABI793 | 5-15 | 1663±184 |
| 9 | hCD46 | 365 | 78 | y | ABI793 | 5-15 | 744±415 |
| 10 | 4-GE | 364 | 29 | y | h5c8 | 25 | n/a |
| 11 | 4-GE | 365 | 16 | y | h5c8 | 25 | n/a |
| 12 | 5-GE | 162 | 14 | y | h5c8 | 25 | n/a |
| 13 | 3-GE | 58 | 21 | n | h5c8 | 25 | n/a |
| 14 | 5-GE | 52 | 21 | y | h5c8 | 25 | n/a |
All monkeys received; Mycophertolate mofetil, Dextran sulfate, Prostacyclicn, Methylprednisolone, Aspirin, Ganciclovir or Valganciclovir, Famotidine, and Heparin as detailed in Table 2.
*
Monkeys 6,8 received two transplants and two courses of ATG.
n/a = not measured
GE (genetically-engineered)
GTKO (α1,3-galactosyltransferase gene-knockout)
hTFPI (human tissue factor pathway inhibitor)
WT (wild-type)
3-GE (GTKO/hCD46/hCD39)
4-GE (GTKO/hCD46/hTFPI/CTLA4-Ig)
5-GE(GTKO/hCD46/hCD39/hTFPI/CTLA4-Ig)